Development and validation of a 10-gene signature for predicting recurrence risk in HR+/HER2- early breast cancer undergoing chemo-endocrine therapy.

Breast · 2025 · PMC12056407 · PMID 40288025

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

did not reach statistical significanceP = 0.057so close (0.05 < p ≤ 0.1)

Notably, in the N2-3 subgroup of the training set, which included only 21 patients, although the same trend was observed, the difference did not reach statistical significance (P = 0.057).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.